

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

1. (Currently amended) A non-naturally occurring single chain protein comprising: i) a first polypeptide having a binding domain polypeptide capable of binding to a target molecule, said binding domain polypeptide comprising a heavy chain variable region, said heavy chain variable region comprising an amino acid substitution or deletion corresponding to amino acid position 11 of a heavy chain variable region at one or more amino acid residues; ii) a second polypeptide comprising a connecting region attached to said first polypeptide; and iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, wherein said non-naturally occurring single-chain protein is capable of at least one immunological activity.

2. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein said binding domain polypeptide is a single chain Fv.

3. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein the one or more amino acid substitution or deletion in said heavy chain variable region is effective to increase expression or stability of said protein relative to a protein without said deletion or substitution.

4. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein said binding domain polypeptide comprises an immunoglobulin light chain variable region polypeptide and an immunoglobulin heavy chain variable region polypeptide.

5. (Currently amended) The ~~[[A]]~~ protein of claim 4 further comprising a second binding domain polypeptide capable of binding a second target molecule, said second binding domain polypeptide comprising an immunoglobulin light chain variable region polypeptide and an immunoglobulin heavy chain variable region polypeptide.

6. (Currently amended) The ~~[[A]]~~ protein of claim 5 wherein the first target molecule and the second target molecule are different.

7. (Currently amended) The ~~[[A]]~~ protein of claim 5 wherein the first target molecule and the second target molecule are the same.

8. (Currently amended) The ~~[[A]]~~ protein of claim 1 further comprising ~~wherein said binding domain polypeptide is a single chain Fv comprising one or more amino acid substitution in~~ corresponding to amino acid positions 9, 10, 11, 12, 108, 110, 112 in said heavy chain variable region.

9. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein said binding domain polypeptide is a single chain Fv comprising an amino acid substitution at position 11 in said heavy chain variable region.

10. (Currently amended) The ~~[[A]]~~ protein of claim 9 wherein the amino acid substituted for the amino acid at position of 11 of the single chain Fv heavy chain variable region is selected from the group consisting of serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, and histidine.

11. (Currently amended) The ~~[[A]]~~ protein of claim 9 wherein the amino acid substituted for the amino acid at position of 11 of the single chain Fv heavy chain variable

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

region is selected from the group consisting of serine, threonine, cysteine, tyrosine, asparagine, and glutamine.

12. (Currently amended) The ~~[[A]]~~ protein of claim 9 where leucine is replaced by serine at position 11.

13. (Currently amended) The ~~[[A]]~~ protein of claim 9 where leucine is replaced by des-leucine at position 11.

14. (Currently amended) The ~~[[A]]~~ protein of claim 12 having an increased recombinant expression or stability relative to said protein not having an amino acid substitution at position 11.

15. (Currently amended) The ~~[[A]]~~ protein of claim 14 wherein the expression of said protein having an amino acid substitution at position 11 is 10-100 fold greater than said protein without a substitution at position 11.

16. (Currently amended) The ~~[[A]]~~ protein of claim 14 wherein said expression is in mammalian cells.

17. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein said binding domain polypeptide is a single chain Fv and the amino acid at position 11 of the heavy chain variable region of said single chain Fv has been deleted.

18. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein said binding domain polypeptide is a single chain Fv and said binding domain polypeptide comprises a light chain variable region, wherein said light chain variable region has an amino acid deletion or substitution at one or more of amino acid positions 12, 80, 81, 83, 105, 106, and 107.

19. (Currently amended) The ~~[[A]]~~ protein of claim 18 wherein the amino acid at position 106 has been substituted or deleted.

20. (Currently amended) The ~~[[A]]~~ protein of claim 2 wherein said binding domain polypeptide binds to a tumor antigen.

21. (Currently amended) The ~~[[A]]~~ protein of claim 2 wherein said binding domain polypeptide binds to an antigen on an immune effector cell.

22. (Currently amended) The ~~[[A]]~~ protein of claim 2 wherein said binding domain polypeptide binds to a cancer cell antigen.

23. (Currently amended) The ~~[[A]]~~ protein of claim 22 wherein said cancer cell antigen is a surface antigen.

24. (Currently amended) The ~~[[A]]~~ protein of claim 22 wherein said cancer cell antigen is an intracellular antigen.

25. (Currently amended) The ~~[[A]]~~ protein of claim 1 wherein said binding domain polypeptide binds to a B cell antigen.

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

26. (Currently amended) The [[A]] protein of claim 25 wherein said B cell antigen is selected from the group consisting of CD19, CD20, CD22, CD37, CD40, CD80, and CD86.

27. (Currently amended) The [[A]] protein of claim 2 wherein said single chain Fv binds to a B cell antigen.

28. (Currently amended) The [[A]] protein of claim 27 wherein said B cell antigen is selected from the group consisting of CD19, CD20, CD22, CD37, CD40, CD80, and CD86.

29. (Currently amended) The [[A]] protein of claim 28 wherein said single chain Fv is selected from the group consisting of HD37 single chain Fv, 2H7 single chain Fv, G28-1 single chain Fv, and 4.4.220 single chain Fv.

30. (Currently amended) The [[A]] protein of claim 2 wherein said single chain Fv is selected from the group consisting of HD37 single chain Fv, 2H7 single chain Fv, G28-1 single chain Fv, FC.sub.2-2, UCHL-1, 5B9, L6, 10A8, 2e12, 40.2.36, G19-4, 1D8, and 4.4.220 single chain Fv.

31. (Currently amended) The [[A]] protein of claim 1 wherein said binding domain polypeptide is an scFv that binds to a B cell differentiation antigen.

32. (Currently amended) The [[A]] protein of claim 31 wherein said B cell antigen is selected from the group consisting of CD19, CD20, CD22, CD37, and CD40.

33. (Currently amended) The [[A]] protein of claim 1 wherein said binding domain polypeptide binds to a target selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD8, CD10, CD11b, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD28, CD30, CD37, CD40, CD43, CD50 (ICAM3), CD54 (ICAM1), CD56, CD69, CD80, CD86, CD134 (OX40), CD137 (41BB), CD152 (CTLA-4), CD153 (CD30 ligand), CD154 (CD40 ligand), ICOS, L6, B7-H1, and HLA class II.

34. (Currently amended) The [[A]] protein of claim 1 wherein said protein is capable of forming a complex comprising two or more of said proteins.

35. (Currently amended) The [[A]] protein of claim 34 wherein said complex is a dimer.

36. (Currently amended) The [[A]] protein of claim 1 wherein said protein is a monomer.

37. (Currently amended) The [[A]] protein of claim 1 coupled to a drug, toxin, immunomodulator, polypeptide effector, isotope, label, or effector moiety.

38. (Currently amended) The [[A]] protein of claim 1 wherein said immunological activity is selected from the group consisting of antibody dependent cell-mediated cytotoxicity, complement fixation, induction of apoptosis, induction of one or more biologically active signals, induction of one or more immune effector cells, activation of cellular differentiation, cellular activation, release of one or more biologically active molecules, and neutralization of an infectious agent or toxin.

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

39. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of induction of biologically active signals by activation or inhibition of one or more molecules selected from the group consisting of protein kinases, protein phosphatases, G-proteins, cyclic nucleotides or other second messengers, ion channels, and secretory pathway components.

40. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of induction of one or more immune effector cells selected from the group consisting of NK cells, monocytes, macrophages, B cells, T cells, mast cells, neutrophils, eosinophils, and basophils.

41. (Currently amended) The ~~[[A]]~~ protein of claim 40 wherein said induction of one or more immune effector cells leads to antibody dependent cell-mediated cytotoxicity or the release of one or more biologically active molecules.

42. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of cellular activation, wherein said activation leads to changes in cellular transcriptional activity.

43. (Currently amended) The ~~[[A]]~~ protein of claim 42 wherein said cellular transcriptional activity is increased.

44. (Currently amended) The ~~[[A]]~~ protein of claim 42 wherein said cellular transcriptional activity is decreased.

45. (Currently amended) The ~~[[A]]~~ protein of claim 38 wherein said one or more biologically active molecules is a protease.

46. (Currently amended) The ~~[[A]]~~ protein of claim 38 wherein said one or more biologically active molecules is a cytokine.

47. (Currently amended) The ~~[[A]]~~ protein of claim 46 wherein said cytokine is selected from the group consisting of monokines, lymphokines, chemokines, growth factors, colony stimulating factors, interferons, and interleukins.

48. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of neutralization of an infectious agent, wherein said infectious agent is a bacterium, a virus, a parasite, or a fungus.

49. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of neutralization of a toxin, wherein said toxin is selected from the group consisting of endotoxins and exotoxins.

50. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of neutralization of a toxin, wherein said toxin is an exotoxin selected from the group consisting of anthrax toxin, cholera toxin, diphtheria toxin, pertussis toxin, E. coli heat-labile toxin LT, E. coli heat stable toxin ST, shiga toxin Pseudomonas Exotoxin A, botulinum toxin, tetanus toxin, Bordetella pertussis AC toxin, and Bacillus anthracis EF.

51. (Currently amended) The ~~[[A]]~~ protein of claim 38 which is capable of neutralization of a toxin, wherein said toxin is an endotoxin selected from the group

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

consisting of saxitoxins, tetrodotoxin, mushroom toxins, aflatoxins, pyrrolizidine alkaloids, phytohemagglutinins, and grayanotoxins.

52. (Currently amended) The [[A]] protein of claim 1 wherein said protein is capable of binding to an intracellular target to effect a cellular function.

53. (Currently amended) The [[A]] protein of claim 1 wherein said binding domain polypeptide comprises a light chain variable region attached to said heavy chain variable region by a binding domain linker, wherein said binding domain linker comprises one or more peptide having a sequence Gly-Gly-Gly-Gly-Ser.

54. (Currently amended) The [[A]] protein of claim 53 comprising three Gly-Gly-Gly-Gly-Ser peptides.

55. (Currently amended) The [[A]] protein of claim 1 wherein said binding domain polypeptide comprises wild type or engineered immunoglobulin variable region obtained from species selected from the group consisting of human, murine, rat, pig, and monkey.

56. (Currently amended) The [[A]] protein of claim 1 wherein said binding domain polypeptide comprises a humanized immunoglobulin variable region.

57. (Currently amended) The [[A]] protein of claim 2 wherein said N-terminally truncated immunoglobulin heavy chain constant region polypeptide comprises an IgG CH2 constant region polypeptide attached to an immunoglobulin heavy chain IgG CH3 constant region polypeptide.

58. (Currently amended) The [[A]] protein of claim 2 wherein said N-terminally truncated immunoglobulin heavy chain constant region polypeptide consist essentially of an IgG CH2 constant region polypeptide attached to an immunoglobulin heavy chain IgG CH3 constant region polypeptide.

59. (Currently amended) The [[A]] protein of claim 2 wherein said N-terminally truncated immunoglobulin heavy chain constant region polypeptide comprises an IgG CH2 constant region polypeptide attached to an immunoglobulin heavy chain IgG CH3 constant region polypeptide.

60. (Currently amended) The [[A]] protein of claim 2 wherein said N-terminally truncated immunoglobulin heavy chain constant region polypeptide consist essentially of an IgG CH2 constant region polypeptide attached to an immunoglobulin heavy chain IgG CH3 constant region polypeptide.

61. (Currently amended) The [[A]] protein of claim 1 wherein said binding domain polypeptide is a single chain Fv that comprises at least a portion of a human constant region.

62. (Currently amended) The [[A]] protein of claim 2 wherein said binding domain polypeptide is a single chain Fv that comprises at least a portion of a human constant region.

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

63. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a naturally occurring hinge region selected from the group consisting of a human hinge or portion thereof, human IgG hinge or a portion thereof, human IgA hinge or a portion thereof, human IgE hinge or a portion thereof, camelid hinge region or a portion thereof, IgG1 llama hinge region or portion thereof, nurse shark hinge region or portion thereof, and spotted ratfish hinge region or a portion thereof.

64. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a human IgE hinge or a portion thereof.

65. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a human IgG1, IgG2, IgG3 or IgG4 hinge region having either zero or one cysteine residue.

66. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a human IgGA hinge region having between zero and two cysteine residues.

67. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a wild type human IgG1 immunoglobulin hinge region.

68. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a glycosylation site.

69. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region has no cysteine residues capable of forming disulfide bonds.

70. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region has one cysteine residue.

71. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a mutated wild-type immunoglobulin hinge region polypeptide comprising no more than one cysteine residue.

72. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region is altered so that said protein has a reduced ability to dimerize.

73. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises three cysteine residues and one proline residue, wherein one or more of said cysteine residues is deleted or substituted and said proline residue is substituted or deleted.

74. (Currently amended) The [[A]] protein of claim 1 wherein said connecting region comprises a mutated wild-type immunoglobulin hinge region polypeptide comprising first, second, and third cysteine residues, where said first cysteine residue is N-terminal to said second cysteine and said second cysteine is N-terminal to said third cysteine, wherein said first cysteine residue is substituted or deleted.

75. (Currently amended) The [[A]] protein of claim 74 wherein said wild-type hinge region polypeptide is from human IgG1.

76. (Original) A non-naturally occurring single chain protein comprising: i) a first polypeptide having a binding domain polypeptide capable of binding to a target

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

molecule, said binding domain polypeptide comprising a heavy chain variable region comprising one or more amino acid deletion or substitution in positions 9, 10, 11, 12, 108, 110, 112; ii) a second polypeptide comprising a connecting region attached to said first polypeptide; and iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, wherein said non-naturally occurring single-chain protein is capable of at least one immunological activity.

77. (Original) A non-naturally occurring single chain Fv protein comprising: i) a first polypeptide having a binding domain polypeptide capable of binding to a target molecule, said binding domain polypeptide comprising a heavy chain variable region wherein leucine is replaced by serine at position 11 in the first framework region of the heavy chain variable region; ii) a second polypeptide comprising a connecting region attached to said first polypeptide; and iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, wherein said non-naturally occurring single-chain protein is capable of at least one immunological activity.

78. (Currently amended) The [[A]] protein of claim 77 further comprising a substitution or deletion of the amino acid at position 10 in the first framework region of the heavy chain variable region.

79. (Currently amended) The [[A]] protein of claim 77 wherein the amino acid substitution at position 11 is effective to increase expression or stability of said single chain Fv protein relative to a single chain Fv protein without said deletion or substitution.

80. (Canceled)

81. (Currently amended) The [[A]] protein of claim 77 wherein said connecting region comprises a proline and first, second, and third cysteine residues, where said first cysteine residue is N-terminal to said second cysteine, and said second cysteine is N-terminal to said third cysteine, and said third cysteine residue is N-terminal to said proline residue.

82. (Currently amended) The [[A]] protein of claim 77 wherein said connecting region comprises an IgA hinge region or portion thereof.

83. (Currently amended) The [[A]] protein of claim 81 where said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, wherein said second cysteine residue is replaced by serine and said proline residue is replaced by serine in the connecting region, and wherein said heavy chain constant region comprises CH2 and CH3 domains from IgG₁.

84. (Currently amended) The [[A]] protein of claim 82 wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, wherein said connecting region comprises a murine IgA hinge or portion thereof, and wherein said heavy chain constant region comprises CH2 and CH3 domains from murine IgA, and wherein said CH3 comprises a deletion or substitution in of four amino acids that render the IgA heavy chain constant region incapable of associating with a J chain polypeptide.

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

85. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a 2H7 single chain Fv binding domain, wherein said first, second, and third cysteine residues in the connecting region are replaced by serine and said proline residue in the connecting region is replaced by serine, wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁ and wherein lysine is replaced by serine at position 322 in said CH2 region.

86. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, wherein in the connecting region said second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG, and wherein lysine is replaced by serine at position 322 in said CH2 region.

87. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG, and wherein proline is replaced by serine at position 331 in said CH2 region.

88. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, wherein in the connecting region said second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁ and wherein proline is replaced by serine at position 331 in said CH2 region.

89. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a 2H7 single chain Fv binding domain, wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG, and wherein threonine is replaced by asparagine at position 256 in said CH2 region.

90. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a 2H7 single chain Fv binding domain, ~~where~~ wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant region comprises 2H7 single chain Fv CH2 and CH3 domains from IgG, ~~where~~ and wherein in the CH2 domain arginine is replaced by glutamine at position 255, threonine is replaced by asparagine at position 256, proline is replaced by alanine at position 257, and glutamic acid is replaced by lysine at position 258.

91. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, ~~where~~ wherein in the connecting region said first, second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG₁, and wherein lysine is replaced by glutamine at position 290 in said CH2 region.

92. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, ~~where~~ wherein in the connecting region said first, second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, wherein said heavy chain constant region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG, and wherein alanine is replaced by proline at position 339 in said CH2 region.

93. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, ~~where~~ in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG₁.

94. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, ~~where~~ wherein in the connecting region said second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG₁.

95. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, ~~where~~ wherein in the connecting region said second cysteine residue is replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG₁.

96. (Currently amended) The ~~[[A]]~~ protein of claim 81 said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, ~~where~~ in the connecting region said first and second cysteine residues are replaced by serine, said heavy chain constant region comprising CH2 and CH3 domains from IgG₁.

97. (Currently amended) The ~~[[A]]~~ protein of claim 81 wherein said single chain protein comprises a single chain Fv binding domain from a FC2-2 hybridoma, ~~where~~ wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG₁.

98. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a UCHL-1 hybridoma, ~~where~~ wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region ~~comprises~~ ~~comprising~~ CH2 and CH3 domains from IgG₁.

99. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 5B9 hybridoma, ~~where~~ wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, ~~where~~ and wherein said heavy chain constant region comprises CH2 and CH3 domains from IgG₁.

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

100. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, ~~where~~ wherein in the connecting region said first, second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁.

101. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a 2H7 hybridoma, ~~where~~ wherein in the connecting region said second and third cysteine residues are replaced by serine and said proline residue is replaced by serine, ~~where~~ and wherein said heavy chain constant region comprises CH2 and CH3 domains from IgG₁.

102. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, ~~where~~ wherein in the connecting region said first and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁.

103. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma comprising a connecting region wherein said third cysteine residue is replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁.

104. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, ~~where~~ wherein in the connecting region said first cysteine residue is replaced by serine, and wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁.

105. (Currently amended) The ~~[[A]]~~ protein of claim 82 wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, wherein said connecting region comprises ~~comprising~~ a murine IgA hinge region, wherein said heavy chain constant region comprises CH2 and CH3 domains from murine IgA and wherein said CH3 domain comprises a deletion or substitution of ~~in~~ four amino acids that render the IgA heavy chain constant region incapable of associating with a J chain polypeptide.

106. (Currently amended) The ~~[[A]]~~ protein of claim 82 wherein said single chain protein comprises a single chain Fv binding domain from a G28-1 hybridoma, wherein said connecting region comprises ~~comprising~~ a human IgA hinge region and said heavy chain constant region comprises CH2 and CH3 domains from human IgA, ~~where~~ wherein said CH3 domain comprises a deletion or substitution of ~~in~~ four amino acids that render the IgA heavy chain constant region incapable of associating with a J chain polypeptide.

107. (Currently amended) The ~~[[A]]~~ protein of claim 81 ~~where~~ wherein said single chain protein comprises a single chain Fv binding domain from a HD37 hybridoma, ~~where~~ wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline residue is replaced by serine, and wherein said heavy chain constant region comprises ~~comprising~~ CH2 and CH3 domains from IgG₁.

Application No.: 10/627,556

Docket No.: 31126/41458CIP2

108. (Currently amended) The [[A]] protein of claim 81 ~~where~~ wherein said single chain protein comprises a L6 single chain Fv binding domain, ~~where~~ wherein in the connecting region said first, second, and third cysteine residues are replaced by serine and said proline ~~reside~~ residue is replaced by serine, and wherein said heavy chain constant region comprises CH2 and CH3 domains from IgG₁.

109. (Currently amended) The [[A]] non-naturally occurring single chain Fv protein comprising: i) a first polypeptide having a binding domain polypeptide capable of binding to a target molecule, said binding domain polypeptide comprising a heavy chain variable region ~~where~~ wherein leucine is replaced by serine at position 11 in the first framework region of the heavy chain variable region; ~~wherein said protein has an increased expression or stability in mammalian cells relative to a protein not having said amino acid substitution;~~ ii) a second polypeptide comprising a connecting region attached to said first polypeptide; and iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, wherein said non-naturally occurring single-chain Fv protein is capable of at least one immunological activity, and wherein said protein has an increased expression or stability in mammalian cells relative to a protein not having said amino acid substitution.